Characteristics | N1 LN subgroups | P value | |||||
---|---|---|---|---|---|---|---|
0–2 | 3–5 | 6–8 | 9–11 | ≥ 12 | Overall | ||
n = 181 | n = 425 | n = 477 | n = 414 | n = 531 | n = 2028 | ||
Gender | 0.289 | ||||||
Male | 103 (56.9) | 246 (57.9) | 276 (57.9) | 245 (59.2) | 337 (63.5) | 1207 (59.4) | |
Female | 78 (43.1) | 179 (42.1) | 201 (42.1) | 169 (40.8) | 194 (36.5) | 821 (40.5) | |
Age (year) | 60.9 ± 9.6 | 60.3 ± 9.5 | 59.5 ± 9.8 | 59.6 ± 9.3 | 59.8 ± 9.0 | 59.9 ± 9.4 | 0.460 |
Tumor size (cm) | 2.4 ± 1.0 | 2.5 ± 1.0 | 2.5 ± 1.0 | 2.6 ± 1.0 | 2.6 ± 1.0 | 2.5 ± 1.0 | 0.027 |
Smoking history | 0.008 | ||||||
No | 115 (63.5) | 238 (56.0) | 268 (56.2) | 224 (54.1) | 259 (48.8) | 1104 (54.4) | |
Yes or ever | 66 (36.5) | 187 (44.0) | 209 (43.8) | 190 (45.9) | 272 (51.2) | 924 (45.6) | |
8th TNM stage | 0.537 | ||||||
IA | 86 (47.5) | 222 (52.2) | 240 (50.3) | 194 (46.9) | 256 (48.2) | 998 (49.2) | |
IB–IIA | 95 (52.5) | 203 (47.8) | 237 (49.7) | 220 (53.1) | 275 (51.8) | 1030 (50.8) | |
Histology | 0.582 | ||||||
Adenocarcinoma | 145 (80.1) | 329 (77.4) | 365 (76.5) | 312 (75.4) | 416 (78.3) | 1567 (77.3) | |
Squamous cell carcinoma | 19 (10.5) | 66 (15.5) | 74 (15.5) | 68 (16.4) | 83 (15.6) | 310 (15.3) | |
Others | 17 (9.4) | 30 (7.1) | 38 (8.0) | 34 (8.2) | 32 (6.0) | 151 (7.4) | |
Differentiation degree | 0.054 | ||||||
Well | 26 (14.4) | 48 (11.3) | 28 (5.9) | 38 (9.2) | 56 (10.5) | 196 (9.7) | |
Moderate | 98 (54.4) | 224 (52.8) | 275 (57.9) | 246 (59.6) | 264 (49.7) | 1107 (54.7) | |
Poor | 57 (31.2) | 153 (35.9) | 174 (36.2) | 130 (31.2) | 211 (39.7) | 725 (35.6) | |
Visceral pleural invasion | 0.605 | ||||||
Negative | 119 (65.7) | 306 (72.0) | 329 (69.0) | 288 (69.6) | 375 (70.6) | 1417 (69.9) | |
Positive | 62 (34.3) | 119 (28.0) | 148 (31.0) | 126 (30.4) | 156 (29.4) | 611 (30.1) | |
Vascular invasion | 0.843 | ||||||
Negative | 168 (92.8) | 399 (93.9) | 442 (92.7) | 391 (94.4) | 496 (93.4) | 1896 (93.5) | |
Positive | 13 (7.2) | 26 (6.1) | 35 (7.3) | 23 (5.6) | 35 (6.6) | 132 (6.5) | |
Number of N2 LNs examined | < 0.001 | ||||||
0–2 | 24 (13.3) | 24 (5.6) | 29 (6.1) | 13 (3.1) | 21 (4.0) | 111 (5.5) | |
3–5 | 29 (16.0) | 62 (14.6) | 66 (13.8) | 54 (13.0) | 53 (10.0) | 264 (13.0) | |
6–8 | 40 (22.1) | 79 (18.6) | 83 (17.4) | 68 (16.4) | 78 (14.7) | 348 (17.2) | |
9–11 | 25 (13.8) | 56 (13.2) | 83 (17.4) | 60 (14.5) | 76 (14.3) | 300 (14.8) | |
12–14 | 20 (11.0) | 72 (16.9) | 69 (14.5) | 65 (15.7) | 72 (13.6) | 298 (14.7) | |
≥ 15 | 43 (23.8) | 132 (31.1) | 147 (30.8) | 154 (37.2) | 231 (43.5) | 707 (34.9) | |
Adjuvant chemotherapy | 0.582 | ||||||
No | 160 (88.4) | 363 (85.4) | 413 (86.6) | 368 (88.9) | 458 (48.2) | 1762 (86.9) | |
Yes or ever | 21 (11.6) | 62 (14.6) | 64 (13.4) | 46 (11.1) | 73 (13.7) | 266 (13.1) | |
Thoracotomy or VATS | 0.176 | ||||||
Thoracotomy | 68 (37.6) | 193 (45.4) | 230 (48.2) | 194 (46.9) | 242 (45.6) | 927 (45.7) | |
VATS | 113 (62.4) | 232 (54.6) | 247 (51.8) | 220 (53.1) | 289 (54.4) | 1101 (54.3) |